S. Estradiol decreases taurine level by reducing cysteine sulfinic acid decarboxylase via the estrogen receptor-␣ in female mice liver. Am J Physiol Gastrointest Liver Physiol 308: G277-G286, 2015. First published November 13, 2014; doi:10.1152/ajpgi.00107.2014.-Cysteine sulfinic acid decarboxylase (CSAD) and cysteine dioxygenase (CDO) are two rate-limiting enzymes in taurine de novo synthesis, and their expressions are associated with estrogen concentration. The present study was designed to determine the relationship between 17␤-estradiol (E 2) and taurine in female mice liver. We initially observed the mice had lower levels of CSAD, CDO, and taurine during estrus than diestrus. We then, respectively, treated the ovariectomized mice, the cultured hepatocytes, and Hep G2 cells with different doses of E 2, and the CSAD and CDO expressions and taurine levels were analyzed. The results showed that E 2 decreased taurine level in the serum and the cultured cells by inhibiting CSAD and CDO expressions. Furthermore, we identified the molecular receptor types through which E 2 plays its role in regulating taurine synthesis, and our results showed that estrogen receptor-␣ (ER␣) expression was much higher than estrogen receptor-␤ (ER␤) in the liver and hepatocytes, and the inhibiting effects of E 2 on CSAD, CDO, and taurine level were partially abrogated in the ICI-182,780-pretreated liver and hepatocytes, and in ER␣ knockout mice. These results indicate that estradiol decreases taurine content by reducing taurine biosynthetic enzyme expression in mice liver. cysteine dioxygenase TAURINE (2-aminoethanesulfonic acid), one metabolic product of cysteine, is a very abundant amino acid in mice (20), and it has been detected in several organs, including the liver (8, 42).
cysteine dioxygenase TAURINE (2-aminoethanesulfonic acid), one metabolic product of cysteine, is a very abundant amino acid in mice (20) , and it has been detected in several organs, including the liver (8, 42) . Tissue taurine concentration varies considerably; it can be as about 20 mol/g in the mouse liver (23) but about 2 mol/g in mouse mammary glands (44) . Hepatic taurine contributes the majority of total body taurine due to its high taurine de novo synthesis capacity and large organ mass. Previous work has documented the functional effects of taurine in the liver, such as promoting taurocholate formation (4), reducing oxidative stress (35) , and decreasing liver fibrosis (36) .
Taurine de novo biosynthesis is mainly through two ratelimited enzymes, cysteine dioxygenase (CDO; EC 1. 13.11.20) and cysteine sulfinic acid decarboxylase (CSAD; EC 4.1.1.29). The uptake and excretion of taurine in the liver are via the sodium/chloride-dependent taurine transporter (TauT; SLC6A6). These genes are expressed in numerous organs, including the liver (29, 34, 45) . However, taurine transporter plays the minor role in the hepatocyte (45) . Taurine biosynthetic enzyme activity in the liver is much higher than other organs (10, 40) , and, between these two enzymes, CSAD behaves in a much direct relation to taurine concentration than CDO (39, 41) . Body taurine homeostasis mainly relies on the expression of these genes.
Estrogen is an important reproductive hormone. In the liver, estrogen and estrogen receptors (ERs) are involved in bile formation (12) , oxidative stress moderation (2) , and liver fibrosis progress (7) . Besides that, its concentration is associated with CSAD and taurine levels in the liver and other organs (19, 28, 44) . In female rat liver, estrogen could reduce the decarboxylation of cysteine sulfinic acid (5) . However, beyond that, it needs to be revealed whether estrogen also adjusts the expression of another taurine biosynthetic enzyme (CDO). Also, the receptor via which estrogen exerts its function is also elusive. Therefore, the precise relationship between estrogen and taurine biosynthesis in female mice needs to be elucidated.
Another metabolic product of cysteine is glutathione (GSH), which is closely related to the intracellular cysteine level in the liver (30) . Its content is also interfered by estradiol (37) . GSH has many beneficial effects in the liver, including reducing oxidative stress and slowing the liver fibrosis process (15) . Because taurine, taurine biosynthetic enzymes, GSH, and E 2 all have related functions in the liver, we focused our study on investigating their interconnection.
To determine whether E 2 regulates the expression level of liver taurine biosynthetic enzymes, to investigate which receptor mediates this regulation, and also to further explore whether the expression level of taurine biosynthetic enzymes has influence on intracellular GSH, we initially analyzed taurine biosynthetic enzymes and taurine levels in the liver, primary hepatocytes, and Hep G2 cells treated with E 2 . We then used an estrogen receptor antagonist and the ER knockout mice to determine the receptor mediating this regulation. Finally, we examined the relation between taurine biosynthetic enzyme expression level and intracellular GSH level in Hep G2 cells. The collective results of the present study indicate that E 2 decreases taurine level by reducing taurine biosynthetic enzyme expression via ER␣ in female mice liver.
MATERIALS AND METHODS
Reagents. 17-␤-Estradiol (E2), taurine, type I collagenase, type IV collagenase, insulin, CaCl 2, disodium selenite, phenol red-free Dulbecco's modified Eagle's medium (DMEM), trypan blue, transferrin, dexamethasone, fetal bovine albumin (FBA), nitroblue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), EDTA, phthaldialdehyde (OPA), 2-hydroxy-1-etanethiol, diaminobenzidine, ␤-estradiol 6-(O-carboxymethyl) oxime, bovine serum albumin (E2-BSA), and anti-GAPDH antibody were purchased from Sigma-Aldrich Chemical (Sigma, St. Louis, MO). CDO antibody was purchased from Abcam (Cambridge, MA). Antibodies of glutamate cysteine ligase catalytic subunit (GCLC) and glutamate cysteine ligase modifier subunit (GCLM) were purchased from Protein Tech Group (Chicago, IL). All other chemicals were purchased from Sinopharm Chemical Reagent (Beijing, People's Republic of China).
Animals and treatments. Adult female C57BL/6 mice were used, and all of the animal experiments were approved by the Chinese Association for Laboratory Animal Science. The mice weighed 25 Ϯ 1 g, were housed at 24 Ϯ 2°C, relative humidity of 55 Ϯ 15%, kept in clean cages under a 14:10-h light-dark cycle, and fed with standard rodent chow. Estrus cycle was determined by microscopic identification of vaginal smears. Female wild-type (WT) mice and ER␣ knockout (KO) mice underwent bilateral ovariectomy (OVX). Experiments were performed 3 wk after the procedure. The OVX mice were treated with varying doses of E 2 by intraperitoneal injection. After E2 treatment, the mice were killed by cervical fracture. Their blood was collected and stored at 4°C overnight for serum collection. The left lateral lobe of the liver was collected, and one part was fixed in 4% (wt/vol) paraformaldehyde (PFA) diluted in phosphate-buffered saline (PBS, pH 7.4) for immunohistochemistry (IHC). The rest of the liver was immediately frozen in liquid nitrogen for CSAD, CDO, and taurine detection. The ER KO mice were purchased from Jackson Laboratory. The ER␣ KO allele symbol is B6.129P2-Esr1 tm1Ksk /J. The ER␤ knockout (ER␤ KO) allele symbol is B6.129P2-Esr2 tm1Unc /J. Genotype identification was performed by separated PCR with specific primers as shown in Table 1 .
Mouse primary hepatocyte culture. The hepatocyte isolation followed an adoption of a modified two-step collagenase perfusion technique (25) . Briefly, in the inferior vena cava we perfused calcium and magnesium-free Dulbecco's-Hanks' balanced salt solution (pH 7.4) containing 1 mM EDTA followed by serum-free Williams' medium E solution (GIBCO, Grand Island, NY) supplemented with 0.1% (wt/vol) collagenase type I, 0.1% (wt/vol) type IV, and 1 mM CaCl 2. The crude hepatocytes were collected by a mechanical operation and filtered through a stainless steel mesh filter (100 m in diameter). The hepatocytes were separated from other cells by centrifuging two times (50 g for 2 min) and purifying over a 45% Percoll gradient (GE Healthcare, Piscataway, PA). Cell count and cell viability were assessed by the Trypan blue exclusion test. The cells were incubated in petri dishes precoated with collagen type I (BD Biosci- ences, San Jose, CA) at a density of 0.5 ϫ 10 6 cells/ml only when cell viability was over 85%. The complete culture medium was Williams' medium E (GIBCO) containing 10% (vol/vol) fetal bovine serum (FBS) (Hyclone, Logan, UT), 1% (vol/vol) antibiotic/antimycotic solution (GIBCO), 100 nM insulin, 100 nM dexamethasone, and 0.3 nM disodium selenite. Later (24 h), the medium was replaced with phenol red-free Williams' medium E (GIBCO) supplemented with 1% (vol/vol) antibiotic/antimycotic solution (GIBCO), 200 nM insulin, and 200 nM dexamethasone, 0.5 nM disodium selenite, 1 mg/l transferrin, and 1 mg/l FBA. After 18 h of starving culture, primary culture hepatocytes were treated with varying doses of E 2. Unless specifically mentioned, the cells were harvested 15 h after E 2 treatments.
Hep G2 cells and 293FT cell culture. 293FT cells were purchased from Invitrogen (Invitrogen, Carlsbad, CA). Hep G2 cells and 293FT cells were maintained in complete DMEM (GIBCO) supplemented with 10% (vol/vol) FBS (Hyclone) and 1% (vol/vol) antibiotic/ antimycotic solution (GIBCO). When cell confluence was Ͼ80%, the cells were passaged by 0.25% (wt/vol) trypsin at a ratio of 1:4. After 18 h of plating, the culture medium was aspirated and replaced with phenol red-free DMEM. Unless specifically mentioned, the harvest times for these cells were 15 h after E 2 treatments.
Real-time PCR assay. Total RNA was extracted with a Takara RNA PLUS extraction kit (Takara Biotechnology, Dalian, People's Republic of China) according to the manufacturer's instruction. Total RNA (1-2 g) was reversed transcribed to cDNA with the Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI). The primers used for real-time PCR assay were purchased from Sangon (Shanghai, People's Republic of China) as shown in Table 2 . The real-time PCR assays were performed on an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA) according to the instructions of SYBR Premix Ex Taq GC (Takara). The analysis was based on the PCR product threshold cycle (C t) values. The ⌬⌬Ct values were the Ct values of the housekeeping gene (GAPDH) (⌬Ct) subtracted from the target gene Ct values such as CSAD. The expression level of the target genes was calculated as 2 ⌬⌬Ct . Western blot assay. The samples were homogenized and centrifuged. The total protein contents were determined by a BCA Protein Assay Kit (Beyotime, Nanjing, People's Republic of China). Samples containing 50 g total proteins were resolved by 5-15% SDSpolyacrylamide gels (wt/vol) and transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). Nonspecific binding sites were blocked by 5% (wt/vol) nonfat milk powder diluted in Tween/Tris-buffered saline (TBST) for at least 2 h at room temperature (RT). The membranes were then incubated with primary antibodies (CSAD 1:10,000, CDO 1:2,000, GCLC 1:1,000, GCLM liver CSAD and CDO protein levels. E and F: serum and liver taurine concentrations. Significant effects of E2 on decreasing CSAD, CDO, and TauT mRNA levels, CSAD and CDO proteins levels, and serum taurine concentration were observed. Liver taurine concentration was not significantly different from the oil control mice. Oil, maize oil (100 l/day). Values are given as means Ϯ SE (n ϭ 4). *P Ͻ 0.05. liver CSAD, CDO, and TauT mRNA levels. C and D: liver CSAD and CDO proteins levels. E and F: serum and liver taurine concentrations. E2 (4 and 40 g/kg) remarkably reduced CSAD and TauT mRNA levels in OVX mice. The significantly decreased levels of CSAD protein, serum taurine, and liver taurine in OVX mice were detected only when the E2 dose was up to 40 g/kg. CDO mRNA level was not significantly decreased with different doses of E2. Con, OVX mice without any injection. Values are given as means Ϯ SE (n ϭ 5). *P Ͻ 0.05. 1:1,000, GAPDH 1:20,000) diluted in TBST buffer overnight at 4°C. The antibody against CSAD was produced by injecting keyhole limpet hemocyanin (KLH)-conjugated phosphorylated peptide into specific pathogen-free New Zealand White rabbits using a standard protocol outlined by Beijing B&M Biotech. The sequences of the synthetic peptides: "MADSKPLRTLDGDPVAV [C]," [C] were used to ligate the KLH. After being washed for 30 min with three changes of TBST, the membranes were incubated with horseradish peroxidaseconjugated secondary antibody (1:20,000) (Zhongshan Bio, Beijing, People's Republic of China) or alkaline phosphatase-conjugated secondary antibody (1:5,000) (Zhongshan) diluted in TBST for 2 h at RT. The signals were exposed on autoradiograph X-ray film (Kodak, Rochester, NY) with a Pierce ECL Kit (Pierce, Rockford, IL) or incubated with NBT/BCIP solution, respectively. All films and membranes were imaged in a Tannon gel imager (Beijing, People's Republic of China). The relative intensities of each protein band were quantified by the Alphaimager 2200 software (Alpha Innotech, San Leandro, CA). The intensity values pertaining to each sample were normalized against the density of GAPDH.
IHC and immunocytochemistry.
The liver samples were dehydrated, embedded in paraffin, and then sliced into 5-m sections. After dewaxing and rehydration, antigen retrieval was performed by microwaving the sections for 20 min in 0.01 M sodium citrate buffer (pH 6.0). After washing with PBS (pH 7.2) for 30 min, nonspecific endogenous peroxidase activity was blocked by 3% (vol/vol) H 2O2 diluted in PBS. Nonspecific binding sites were then blocked by 10% normal goat serum diluted in PBS at least for 3 h at RT. For CSAD detection, the sections were first incubated with rabbit anti-mouse CSAD antibody (1:200) diluted in PBS overnight at 4°C. After being washed with PBS for 30 min, the sections were incubated with biotinylated goat anti-rabbit IgG (1:200) (Zymed Laboratories, San Francisco, CA) for 2 h at RT. After being washed with PBS for 30 min, the sections were incubated with streptavidin peroxidase complex (1:200) (Zymed Laboratories) for 2 h at RT. Finally, the signals were visualized by incubating the sections with 0.05 mol/l Tris·HCl (pH 6.5) containing 0.06% (wt/vol) diaminobenzidine and 0.03% (vol/vol) H 2O2. For ER␣ detection, the dilution ratios for the three antibodies were anti-ER␣ (NCL-ER-LH2) antibody (1:30) (Novocas- g/kg E2-reducing CSAD, CDO, and taurine levels were abrogated in the 40 g/kg ICI 2-h-pretreated mouse liver. F and H: primary hepatocyte CSAD mRNA levels. G: primary hepatocyte CDO and TauT mRNA levels. ICI (100 nM) and 100 nM ␤-estradiol 6-(O-carboxymethyl) oxime (BSA-E2, bovine serum albumin) did not possess the capacity of 100 nM E2 on deceasing CSAD, CDO, and TauT mRNA levels in primary hepatocytes. Values are given as means Ϯ SE from 3 independent experiments. *P Ͻ 0.05. tra, Newcastle, UK), sheep anti-mouse IgG (1:50) (SAPU, Carluke, UK). and mouse alkaline phosphatase anti-alkaline phosphatase complex (1:50) (Serotec, Oxford, UK). The anti-ER␣ sections were visualized by incubating these sections with NBT/BCIP solution for 4 -10 min. The sections for CSAD and ER␣ detection were all dehydrated and mounted for photograph collection.
For immunocytochemistry (ICC), primary hepatocytes and Hep G2 cells were fixed with 4% PFA for 20 min and then treated with cold methanol for 10 min. Subsequent procedures were as the protocol of IHC for CSAD and ER␣ but without the step of antigen retrieval.
Measurement of taurine. The samples were weighed, homogenized, and deproteinized. After centrifuging at 14,000 g for 20 min, the supernatant was loaded in a dual-bed syringe containing cationexchange resin to remove other amino acids. After L-glutamine was added as an internal standard, the samples were filtered through a 0.22-m PVDF membrane filter (Millipore). Before these samples were automatically analyzed in Beckman Coulter HPLC equipment (Beckman Instruments, Fullerton, CA), they were derivatized with OPA solution [20 mg OPA, 2 ml methanol, 80 l 2-hydroxy-1-ethanethiol, and 18 ml 0.1 M borate buffer (pH 9.6)] for 3 min. The detection wavelength was set at 340 nm. The flow rate was 1.1 ml/min. The mobile phase contained a mixture of 0.1 M NaH 2PO4 and 1.3 mM Na2HPO4 in water/methanol (Fisher Scientific, Pittsburgh, PA) (50:50 vol/vol) (pH 4.7). The separation was performed on a Waters Symmetry C18 Column (4.6 m, 150 mm ϫ 5 mm) (Waters, Milford, MA) at 30°C. The retention time for glutamine and taurine was around 3 and 4.95 min, respectively.
Plasmid construction. Various lengths of CSAD promoter (Ϫ1,919 to ϩ29, Ϫ859 to ϩ29, Ϫ440 to ϩ29, Ϫ227 to ϩ29, and Ϫ168 to ϩ29) were amplified with specific primers containing specific restriction enzyme-cutting sites and inserted in a pGL3.0-basic luciferase reporter vector (Promega) in the sense orientation, as presented in a schematic diagram (see Fig. 9A ). The expression vectors of ER␣, CDO, and CSAD were constructed by inserting the full-length coding Fig. 7 . Taurine biosynthetic enzyme and taurine levels in ER knockout (KO) mice. A and B: liver CSAD, CDO, and TauT mRNA levels. C and D: liver CSAD and CDO protein levels. E and F: serum and liver taurine concentrations. ER␣ KO mice had siginifcantly increased CSAD and CDO mRNA and protein expression levels compared with ER wild-type (WT) mice, whereas ER␤ KO mice had decreased CSAD levels compared with ER␤ heterozygote (HE) mice. Taurine contents in ER KO mice compared with their corresponding control mice showed no significant difference. Values are given as means Ϯ SE (n ϭ 5). *P Ͻ 0.05. Fig. 8 . Taurine biosynthetic enzyme and taurine levels in OVX ER␣ KO mice. A and B: liver CSAD, CDO, and TauT mRNA levels. C and D: liver CSAD and CDO protein levels. E and F: serum and liver taurine concentrations. Mice CSAD and CDO mRNA and protein levels did not respond to E2 treatment. However, the TauT mRNA expression level was increased after E2 treatment in the OVX ER␣ KO mice. G: hepatocyte CSAD mRNA levels. H: hepatocyte CSAD protein levels. E2 (100 nM) decreased the CSAD level only in the hepatocytes from the ER␤ KO mice but not from the ER␣ KO mice. Values are given as means Ϯ SE (n ϭ 5). *P Ͻ 0.05. sequence (CDS) in the pcDNA3.1 vector (Invitrogen) in the sense orientation. As shown in Fig. 9B , the difference between wild ER␣ and truncated ER␣ (tER␣) vectors is the deletion of the DNA-binding domain. All vectors were confirmed by DNA sequence analysis from Sangon (Beijing, People's Republic of China).
Luciferase assay and measurement of intracellular GSH. The ER␣ vector, CSAD luciferase reporter vector, and pTK-Renilla vector (Promega) were mixed at a ratio of 10:4:1. The mixture was then transfected into 293FT cells with Vigofect (Vigorous Biotechnology, Beijing, People's Republic of China) according to the manufacturer's protocol. The cells were harvested 12 h after E2 treatment. After three washes with PBS, Firefly and Renilla luciferase activities from the cell lysates were first incubated with the Dual-Luciferase Assay Kit (Vigorous) according to the manufacturer's instructions and then measured on a Modulus Microplate Multimode Reader (Turner BioSystems, Sunnyvale, CA) according to the technical manual. The values were calculated as the ratio of Firefly luciferase activity to Renilla luciferase activity. For GSH and oxidized glutathione (GSSG) assay, we followed the instructions of the kit purchased from Promega.
Statistical analysis. Data were analyzed by one-way ANOVA, followed by a Student's t-test. All values are expressed as means Ϯ SE. A P value Ͻ0.05 was considered significant.
RESULTS

Taurine and taurine biosynthetic enzyme expression level during estrus and diestrus.
To determine the relationship between the global estrogen and taurine homeostasis, we initially assessed the hepatic CSAD and CDO expression levels and taurine level in the liver and serum at estrus and diestrus stages, two distinguishable stages during the estrus cycle. The results showed the mRNA and protein levels of CSAD and CDO were remarkably lower at estrus than at diestrus. Meanwhile, the serum and liver taurine concentrations were well correlated with the taurine biosynthetic enzyme expression (CSAD and CDO) levels. However, the TauT mRNA expression level did not have any obvious change (Fig. 1) . Taking into account that mice plasma estrogen is higher during estrus and proestrus than diestrus (31), the inverse correlation between the expression of taurine biosynthetic enzymes and the global estrogen level suggests estrogen may reduce taurine de novo biosynthesis.
Estradiol reduced taurine level and taurine biosynthetic enzyme expression both in vivo and in vitro. Next, we used the OVX mice model with and without an estrogen replacement to mimic the two stages during the estrus cycle. CSAD and CDO mRNA and protein levels plus with the TauT mRNA expression level were reduced after 1 wk of estrogen replacement (Fig. 2, A-D) . Moreover, the increment of serum taurine concentration exhibited in OVX mice was completely reversed by E 2 replacement (Fig. 2E) . However, E 2 had no obvious influence on the liver taurine concentration (Fig. 2F) . The above results supported the hypothesis that estradiol negatively regulated taurine concentration.
To further assess whether a dose-dependent manner of E 2 -reducing CSAD exists, we administrated 0.4, 4, and 40 g/kg E 2 in the OVX mice and then CSAD, CDO, and TauT mRNA levels were analyzed after 15 h. The results showed that both 4 and 40 g/kg E 2 -treated mouse liver had significantly decreased hepatic mRNA levels of CSAD, CDO, and TauT, whereas the significant decline of the liver CSAD protein expression level and liver and serum taurine levels was detected only when the E 2 concentration was up to 40 g/kg (Fig. 3) .
Based on the above in vivo experiments, we further evaluated the function of estradiol on taurine biosynthesis in cultured hepatocytes and Hep G2 cells. The primary hepatocytes were treated with 1, 10, 50, and 100 nM E 2 , and the CSAD and CDO mRNAs were assessed after 3, 6, 9, 12, and 15 h of E 2 treatments. The PCR results showed that 9-, 12-, and 15-h E 2 treatments significantly decreased CSAD and CDO mRNA expression levels. However, the CSAD mRNA was more Fig. 9 . A schematic representation and deletion assay of the CSAD promoter. A: schematic representation of the CSAD promoter reporter vectors. B: schematic representation of ER␣ and truncated ER␣ (tER␣). C: 100 nM E2 reduced the Ϫ1,919 to ϩ29 luciferase activity on the condition of coexpressing ER␣. D: 100 nM E2 suppressed Ϫ1,919 to ϩ29, Ϫ859 to ϩ29, and Ϫ440 to ϩ29 luciferase activities with coexpression of ER␣. LUC, luciferase. Values are given as means Ϯ SE from 3 independent experiments. *P Ͻ 0.05.
sensitive to E 2 treatment than the CDO mRNA (Fig. 4, A and  B) . Furthermore, 15-h E 2 treatments with all of doses resulted in the significant decline of the level of CSAD protein (Fig.  4C) , whereas the significant reduction of hepatocyte taurine concentration was detected only when the E 2 concentration was up to 100 nM (Fig. 4D) .
In Hep G2 cells, 10 and 100 nM E 2 significantly decreased CSAD mRNA and protein levels after 15 h (Fig. 4, E and G) . In addition, our results showed that 100 nM E 2 treatment significantly decreased CDO and TauT mRNA expression levels (Fig. 4F) . Hep G2 cell taurine content was also reduced by 10 and 100 nM E 2 after 15 h (Fig. 4I) . These in vivo and in vitro results indicate that E 2 negatively regulates taurine content.
Estradiol exerted its functional effect on taurine and taurine biosynthetic enzymes via ER␣. To answer whether efffects of E 2 on the taurine biosythetic enzyme expression level and taurine content rely on ERs, we assessed the molecular types of ERs in liver, hepatocytes, and Hep G2 cells. The RT-PCR results showed that ER␣ was dominant in all of the examined cells (Fig. 5A) . Consistent with the RT-PCR results, IHC and ICC results further demonstrated CSAD and ER␣ were coexpressed in the liver, primary hepatocytes, and Hep G2 cells (Fig. 5, B and C) . In addition, a mutual restrained staining pattern was observed in the liver.
Because CSAD and ER␣ were coexpressed in primary hepatocytes and Hep G2 cells, to further determine which ER mediates the E 2 effect, we used an estrogen receptor antagonist, ICI-182,780, and an ER KO mouse model. Notably, the reductions of CSAD and CDO mRNAs level, CSAD protein level, and taurine level after E 2 administration were abrogated in the ICI-182,780 2 h pretreated liver (Fig. 6, A-E) . This blocking effect of ICI-182,780 on E 2 -reducing CSAD, CDO, and TauT mRNA expression level in the liver was also detected in primary hepatocytes with the exception on the CDO mRNA level (Fig. 6, F and G) . In addition, the CSAD mRNA level in primary hepatocytes did not respond to E 2 -BSA treatment (Fig. 6H) .
From ER KO mice, we found that ER␣ KO mice had increased CSAD, CDO, and TauT mRNA expression level compared with WT mice. By contrast, ER␤ KO mice had slightly decreased CSAD, CDO, and TauT mRNA expression level compared with ER␤ heterozygote mice (Fig. 7, A and B) . The protein levels of CSAD and CDO mirrored the results of their mRNA expression (Fig. 7, C and D) . However, taurine level in the ER KO mice did not significantly differ from the level in control mice (Fig. 7, E and F) .
We furthermore analyzed the levels of taurine biosynthetic enzymes and taurine in ER␣ KO mice and found that their levels were not remarkably responsive to either an ovariectomy procedure or an estrogen replacement. However, the expression level of TauT mRNA was increased after E 2 treatment (Fig. 8, A-F) . Meanwhile, E 2 restrained its ability to reduce the abundance of CSAD mRNA and protein level only in hepatocytes from the ER␣ KO mice but not from the ER␤ KO mice (Fig. 8, G and H) .
In thought that E 2 affected mRNA expression mainly through ER␣, we performed a dual-luciferase assay and found E 2 -reducing CSAD (Ϫ1,919 to ϩ29) luciferase activity only when ER␣ was cotransfected (Fig. 9C) . To further analyze the bund part of ER␣ on the CSAD promoter, we transfected with various truncated promoters and found that 100 nM E 2 dramatically suppressed Ϫ1,919 to ϩ29, Ϫ859 to ϩ29, and Ϫ440 to ϩ29 luciferase activities (Fig. 9D) . Taken together, these data suggest that ER␣ is responsible for estradiol's effect on CSAD mRNA expression.
Taurine biosynthetic enzyme expression level was not associated with intracellular GSH level. Finally, to determine whether E 2 reducing the expression level of taurine biosynthetic enzymes was associated with intracellular GSH, we overexpressed the taurine biosynthetic enzymes in Hep G2 cells and then analyzed the intracellular GSH content, GSH- GCLC and GCLM mRNA levels. E and F: GCLC and GCLM protein levels. The GSH content and GSH-to-GSSG ratio were not directly with taurine biosynthetic enzyme expression levels. Values are given as means Ϯ SE from 3 independent experiments. CSAD, 1 g CSAD vector; CDO, 1 g CDO vector; CSAD ϩ CDO, 0.5 g CSAD vector and 0.5 g CDO vector. *P Ͻ 0.05.
to-GSSG ratio. The overexpression efficiency was checked (Fig. 10A) . The results showed the GSH content and GSH-to-GSSG ratio in all of these overexpressed groups did not have significant difference compared with the control (Fig. 10, B and  C) . Besides that, the GSH sythetic enzyme GCLC/GCLM mRNA and protein levels in Hep G2 cells incresed after taurine biosynthetic enzyme overexpression compared with the level in the control group (Fig. 10, D-F) .
DISCUSSION
CSAD has been identified as the main enzyme for the decarboxylation of cysteine sulfinic acid. Our study is in agreement with a previous report (5) showing that the enzymatic activity and abundance of CSAD in the liver increase after an ovariectomy procedure and decrease after E 2 replacement. Besides that, we also found estrogen reduced taurinerelated gene, CDO, and TauT expressions. Among these three genes, the CSAD was most sensitively responsive to E 2 treatment, and this may be because its protein has a longer half-life than CDO (21) . Finally, we clarify the relations among liver taurine biosynthetic enzyme expression levels, taurine content, and E 2 based on the following results. First, we obtained a parallel result of hepatic taurine levels with taurine biosynthetic enzyme expression level elicited by E 2 treatment. Next, the associated reduction of taurine level in serum suggests that the process of taurine synthesis and excretion from the liver (14) combined with absorption and reabsorption from other organs (1), to some extent, which are regulated by E 2 . However, in the long-term E 2 -treated liver or in ER KO mice, taurine levels in the liver and/or the serum were not always parallel with the expression level of taurine biosynthetic enzymes. This may be because serum taurine was also regulated by TauT expression (3, 17, 18) . Because TauT has a minor contribution to the total taurine concentration in hepatocytes (45), we could assume that the abundance of taurine biosynthetic enzymes determines the content of taurine in the liver and hepatocytes. E 2 exerts its function through many signaling pathways. Our observations demonstrate that the classic ER␣ plays an indispensable role in estradiol's effect on taurine biosynthetic enzyme expression. Those results achieved from ICI-182,780 pretreatment and the addition of E 2 -BSA experiments exclude the roles of G protein-coupled receptor 30 and nonclassic ERs participating in 15-h E 2 -treated hepatocytes (6, 11, 33) . Also, the data from ER KO mice have identified ER␣ as the pivotal receptor mediating estradiol's effect.
Based on our observations that taurine biosynthetic enzyme protein levels nearly always well parallel with their mRNA levels, it is conceivable that E 2 mainly regulates taurine biosynthetic enzymes on the transcriptional level (32, 38) . Our dual-luciferase results supported this hypothesis. Analysis of the CSAD promoter suggests that there are three possible half-estrogen response elements (13, 16, 24) . To determine which one is the key element that interacts with ER␣, further explorations are needed.
Taurine and glutathione are two metabolic products of cysteine and methionine. A previous report has shown that both of them are mainly synthesized in liver (14) . Therefore, a competitive relation between taurine and glutathione suggests that the oversynthesis of taurine may reduce the intracellular GSH.
Consistent with this hypothesis, CDO overexpression decreasing glutathione level confirms such a hypothesis (9) . The liver-specific knockout of CDO mice has an increased liver glutathione level (43) . However, our results did not support this hypothesis. This may be due to the increment of GCLC/GCLM expression caused by intracellular cysteine depletion in the Hep G2 cells (26, 27) .
The effect of E 2 -reduced CSAD and CDO expression in the liver is directly associated with taurine de novo synthesis, but this regulatory effect, to some extent, was not inconsistent with the synergetic effect between E 2 and taurine in the progress of fibrosis (36, 46) . This may be interpreted because E 2 -reduced CSAD and CDO expression also disturbed the homeostasis of sulfur-containing amino acids (9, 22) . Therefore, the functional effect of E 2 on the taurine biosynthetic enzyme expression is associated not only with taurine homeostasis but also sulfur compound homeostasis.
In conclusion, our results clearly demonstrate that estradiol decreases taurine concentration mainly via the reduction of taurine biosynthetic enzyme expression level through the ER␣. The expression level of taurine biosynthetic enzymes is not directly connected with intracellular GSH level. Further studies are needed to explore the role of taurine biosynthetic enzymes participating in liver diseases.
